An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
- Registration Number
- NCT00932451
- Lead Sponsor
- Pfizer
- Brief Summary
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1069
- histologically or cytologically proven diagnosis of non-small cell lung cancer
- positive for the ALK fusion gene (test provided by either a central laboratory. Local laboratory may be used for certain cases)
- may have received pemetrexed or docetaxel from previous Phase 3 trial (A8081007) and discontinued treatment due to Response Evaluation Criterion in Solid Tumors (RECIST)-defined progression. or, once the primary endpoint of Study A8081007 has been analyzed and the results made available, at any time without RECIST-defined progression.
- Tumors can be measurable or non measurable
- prior treatment with PF-02341066
- received no prior systemic treatment, chemotherapy or EGFR tyrosine kinase inhibitor, for advanced non-small cell lung cancer
- current enrollment in another therapeutic clinical trial
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description PF-0231066 PF-02341066 -
- Primary Outcome Measures
Name Time Method Objective Response Rate 6 years The objective response rate (ORR) as a measure of anti-tumor efficacy of oral PF-02341066 in participants with advanced NSCLC with an ALK gene translocation or inversion after failure of at least one line of chemotherapy.
Percentage of Participants With Adverse Events 6 years Incidence of adverse events and laboratory abnormalities (severity graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\], version 4.0).
- Secondary Outcome Measures
Name Time Method Duration of Response (DR) 6 years DR was defined as the time from the first documentation of objective tumor response (CR or PR) that was subsequently confirmed, to the first documentation of objective tumor progression or to death on study due to any cause, whichever occurred first. DR (in months) was calculated as (first date of PD or death - first date of CR or PR that was subsequently confirmed + 1)/30.4.
Time to Tumor Response (TTR) 6 years TTR was defined as the time (in weeks) from the date of Cycle 1 Day 1 dose to first documentation of objective tumor response (CR or PR) that was subsequently confirmed. For participants proceeding from PR to CR, the onset of PR was taken as the onset of response.
Disease Control Rate (DCR) 6 years DCR at 6 and 12 weeks was defined as the percentage of participants with a confirmed CR, confirmed PR, or SD (according to RECIST v 1.1) at 6 weeks and 12 weeks, respectively.
Progression Free Survival (PFS) 6 years PFS was defined as the time from the date of the Cycle 1 Day 1 dose to the date of the first documentation of objective tumor progression or death on study due to any cause, whichever occurred first.
Overall Survival (OS) 6 years OS was defined as the time from the Cycle 1 Day 1 dose to the date of death due to any cause. OS (in months) was calculated as (date of death - date of Cycle 1 Day 1 dose + 1)/30.4.
Probability of Survival 6 years Six-month and 1-year survival probabilities were defined as the probabilities of survival at 6 months and 1 year, respectively, after the date of the Cycle 1 Day 1 dose based on the Kaplan-Meier estimate.
Plasma Concentrations of Crizotinib (PF-02341066) and Its Metabolite PF-06260182 6 years Plasma concentrations of crizotinib (PF-02341066) and its metabolite PF-06260182. The method of dispersion is % coefficient of variation.
Molecular Profiling (ALK Status) Descriptive Statistics for ALK Percentage of Positive Cells by Central Laboratory Test (SA [ALK Positive by IUO] Population) 6 years Molecular profiling outcomes included:Types of EML4-ALK fusion variants and ALK protein expression; Although a secondary objective was defined to explore the relationship of ALK gene fusion to the presence of ALK protein and fusion transcript, no additional analyses of ALK fusion variants or ALK protein were performed for technical reasons. Analyses of change from Baseline in the expression of biomarkers relevant to signaling pathways were not performed because paired Baseline and on-treatment (Cycle 2) tumor tissue required for the analysis, which were to be collected on an optional basis, were not available.
Patient Reported Outcomes (PROs) of Health-related Quality of Life (HRQoL): Mean Change From Baseline of EQ-5D Visual Analog Score (VAS) Scale 6 years The EQ-5D descriptive system measured a patient's health state on 5 dimensions which included: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The respondent's self-rated health was assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by the EQ-VAS. n is the number of participants who completed the scale at baseline and at the respective Cycle.
Genotypes of Alleles Possibly Associated With Adverse Hepatic Drug Reactions (Pharmacogenomic Evaluable Population) 6 years The frequency of the candidate gene alleles, HLA-DQA1\*02:01, HLA-DQB1\*02:02, HLA-DRB1\*07:01 and TNXB/rs12153855, were measured in alanine transaminase (ALT) Cases and ALT Controls to evaluate if there were statistically significant associations that would support or suggest any predictive (ie, diagnostic) value of these markers in identifying participants who were at increased risk for hepatic toxicity. The frequency of 2 additional HLA gene alleles, HLA-B\*57:01 and HLA-DRB1\*15:01, were also measured in ALT Cases and ALT Controls. ALT Cases are defined as those patients with a baseline ALT of ≤1xULN and at least one on-treatment ALT assessment of \>3x upper limit of normal (ULN), and ALT Controls represent those patients with baseline and on-treatment assessments of ALT of ≤1xULN.
QTc Prolongation in Participants 6 years The percentage of participants with maximum post-dose QTcF/QTcB (\<450, 450 - \<480, 480 - \<500, and ≥500 msec) were evaluated.
Mean Change From Baseline in QLQ-C30 Global Quality of Life Scores. 6 years The EORTC QLQ-C30 consists of 30 questions which assess five functional domains (physical, role, cognitive, emotional, and social), global health status/quality of life, disease/treatment related symptoms (fatigue, pain, nausea/vomiting, dyspnea, appetite loss, sleep disturbance, constipation, and diarrhoea), and the perceived financial impact of disease. n is the number of participants who completed the scale at baseline and at the respective Cycle. The subscales of the EORTC QLQ-C30 were scored based on the EORTC scoring manual. The transformed scores range from 0-100. Higher scores indicate higher ("worse") symptom severity, higher ("better") functioning, and better global QoL. Negative change from Baseline scores indicate an improvement in symptoms, decreased functioning, or decreased QoL, while positive change scores indicate an increase in functioning, increased QoL, or deterioration in symptoms.
Mean Change From Baseline of EORTC QLQ-C30 Functional and Symptom Scale Scores 6 years The EORTC QLQ-C30 consists of 30 questions which assess five functional domains (physical, role, cognitive, emotional, and social), global health status/quality of life, disease/treatment related symptoms (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, sleep disturbance, constipation, and diarrhoea), and the perceived financial impact of disease. n is the number of participants who completed the scale at baseline and at the respective Cycle. The subscales of the EORTC QLQ-C30 were scored based on the EORTC scoring manual. The transformed scores range from 0-100. Higher scores indicate higher ("worse") symptom severity, higher ("better") functioning, and better global QoL. Negative change from Baseline scores indicate an improvement in symptoms, decreased functioning, or decreased QoL, while positive change scores indicate an increase in functioning, increased QoL, or deterioration in symptoms.
Mean Change From Baseline of QLQ-LC13 Scale Scores 6 years The QLQ-LC13 consists of 1 multi-item scale and 9 single items that assess specific symptoms (dyspnoea, cough, hemoptysis, and site-specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer patients. n is the number of participants who completed the scale at baseline and at the respective Cycle. The subscales of the EORTC QLQ-LC13 were scored based on the EORTC scoring manual. The transformed scores range from 0-100. Higher scores indicate higher ("worse") symptom severity, higher ("better") functioning, and better global QoL. Negative change from Baseline scores indicate an improvement in symptoms, decreased functioning, or decreased QoL, while positive change scores indicate an increase in functioning, increased QoL, or deterioration in symptoms.
Percentage of Participants With Visual Symptom Assessment Questionnaire (VSAQ-ALK) 6 years The participants who responded to the question: "Have you experienced any visual disturbances?" Only the participants who answered yes were instructed to complete the rest of the questionnaire. N was the number of participants who had completed the first question.
Trial Locations
- Locations (259)
Ronald Reagen University of California-Los Angeles Medical Center
🇺🇸Los Angeles, California, United States
Emory University Hospital Midtown
🇺🇸Atlanta, Georgia, United States
Emory Clinic
🇺🇸Atlanta, Georgia, United States
Emory University Clinic
🇺🇸Atlanta, Georgia, United States
Georgia Cancer Specialists - Administrative Annex
🇺🇸Atlanta, Georgia, United States
James Care in Kenny
🇺🇸Columbus, Ohio, United States
Penn Presbyterian Medical Center
🇺🇸Philadelphia, Pennsylvania, United States
University of Texas Southwestern University Hospital - Zale Lipshy
🇺🇸Dallas, Texas, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
University of Chicago Medical Center (Attn: J Pi PharmD / A. Patel Pharm D)
🇺🇸Chicago, Illinois, United States
Massachusette General Hospital
🇺🇸Boston, Massachusetts, United States
Beth Isreal Deaconess Medical Center, Pharmacy FD B18
🇺🇸Boston, Massachusetts, United States
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
Beth Isreal Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute/Pharmacy
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
The University of Texas
🇺🇸Houston, Texas, United States
Swedish Cancer Institute
🇺🇸Seattle, Washington, United States
University of Washington Medical Center
🇺🇸Seattle, Washington, United States
Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
Swedish Medical Center
🇺🇸Seattle, Washington, United States
Drug Shipping Address: Ronald Reagen University of California-Los Angeles
🇺🇸Los Angeles, California, United States
UCLA Opthalmic Oncology Center
🇺🇸Los Angeles, California, United States
Hawaii Medical Center East
🇺🇸Honolulu, Hawaii, United States
Cancer Center of South Florida Foundation, Inc.
🇺🇸Lake Worth, Florida, United States
Monroe Medical Associates
🇺🇸Munster, Indiana, United States
UCSD Medical Center - La Jolla
🇺🇸La Jolla, California, United States
Stanford University-Cancer Center
🇺🇸Palo Alto, California, United States
Ingalls Memorial Hospital
🇺🇸Harvey, Illinois, United States
Memorial Cancer Center (West)
🇺🇸Pembroke Pines, Florida, United States
Medical College of Georgia
🇺🇸Augusta, Georgia, United States
Memorial Cancer Institute
🇺🇸Hollywood, Florida, United States
Redwood Regional Medical Group Inc
🇺🇸Santa Rosa, California, United States
Georgia Cancer Specialists-Stemmer
🇺🇸Decatur, Georgia, United States
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Massachussetts General Hospital
🇺🇸Boston, Massachusetts, United States
University of New Mexico Eye Clinic
🇺🇸Albuquerque, New Mexico, United States
Karmanos Cancer lnstitute at Farmington Hllls
🇺🇸Farmington Hills, Michigan, United States
Memorial Sloan-Kettering Cancer Center: Rockefeller Outpatient Pavilion
🇺🇸New York, New York, United States
Springmill Medical Clinic
🇺🇸Indianopolis, Indiana, United States
Barnes-Jewish Hospital
🇺🇸St. Louis, Missouri, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
University of New Mexico Cancer Center
🇺🇸Albuquerque, New Mexico, United States
Presbyterian Hospital Cancer Center
🇺🇸Charlotte, North Carolina, United States
The Community Hospital
🇺🇸Munster, Indiana, United States
Washington University School of Medicine
🇺🇸St. Louis, Missouri, United States
SUNY Upstate Medical University, Regional Oncology Center
🇺🇸Syracuse, New York, United States
Long Island Jewish Medical Center
🇺🇸New Hyde Park, New York, United States
IP Shipment: CUMC Research Pharmacy
🇺🇸New York, New York, United States
Department of Medical Oncology
🇮🇪Galway, Ireland
Centre Georges-François Leclerc
🇫🇷Dijon, France
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada
Nanjing Bayi Hospital
🇨🇳Nanjing, Jiangsu, China
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Southern Oncology Specialists
🇺🇸Huntersville, North Carolina, United States
Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians
🇺🇸Syracuse, New York, United States
Shanghai Chest Hospital/Department of Pulmonary Medicine
🇨🇳Shanghai, China
St. Mary's Hospital Center
🇨🇦Montreal, Quebec, Canada
NSLIJ Health System/Monter Cancer Center
🇺🇸Lake Success, New York, United States
UT Southwestern Medical Center - Simmons Cancer Center Pharmacy
🇺🇸Dallas, Texas, United States
MBAL Voennomeditsinska Academia, MMA HAT Sofia
🇧🇬Sofia, Bulgaria
Centre Antoine Lacassagne
🇫🇷NICE Cedex 2, France
UT Southwestern University Hospital - William P. Clements, Jr
🇺🇸Dallas, Texas, United States
Presbyterian Hospital Huntersville
🇺🇸Huntersville, North Carolina, United States
Associacao Hospital de Caridade de Ijui
🇧🇷Ijui, RS, Brazil
The Ottawa Hospital Cancer Center
🇨🇦Ottawa, Ontario, Canada
Columbia University Medical Center
🇺🇸New York, New York, United States
Pharma Resource
🇺🇸East Providence, Rhode Island, United States
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
Ospedale San Luca
🇮🇹Lucca, Italy
Alberta Health Services, Holy Cross Site
🇨🇦Calgary, Alberta, Canada
Farmacia Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Centro C.O.E.S., A.O. San Giovanni Battista Le Molinette
🇮🇹Torino, Italy
Centre Francois Baclesse
🇫🇷Caen Cedex 05, France
Jewish General Hospsital
🇨🇦Montreal, Quebec, Canada
Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira - ICESP
🇧🇷Sao Paulo, SP, Brazil
National Kyushu Cancer Center/Department of Thoracic Oncology
🇯🇵Fukuoka, Japan
Office of Dr. John McWhae
🇨🇦Calgary, Alberta, Canada
Hospital Cochin
🇫🇷Paris, France
Westdeutsches Tumorzentrum, Universitaetsklinikum Essen, Innere Klinik - Tumorforschung
🇩🇪Essen, Germany
Fundacao Hospital Amaral Carvalho
🇧🇷Jau, Sao Paulo, Brazil
Nuovo Ospedale San Gerardo
🇮🇹Monza, Italy
SC Oncologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia
🇮🇹Perugia, Italy
Hopital Albert Michallon
🇫🇷Grenoble Cedex 09, France
Montreal General Hospital
🇨🇦Montreal, Quebec, Canada
Hospital Sao Lucas da PUCRS
🇧🇷Porto Alegre, RS, Brazil
The Ohio State University Hospital East
🇺🇸Columbus, Ohio, United States
Vincent Armenio, MD
🇺🇸East Providence, Rhode Island, United States
Chris O'Brien Lifehouse
🇦🇺Camperdown, New South Wales, Australia
Abramson Cancer Center of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Hopital Notre-Dame du Centre Hospitalier de l'Universite de Montreal (CHUM)
🇨🇦Montreal, Quebec, Canada
Royal Adelaide Hospital, Department of Medical Oncology
🇦🇺Adelaide, South Australia, Australia
Ambulantes Krebszentrum Hamburg
🇩🇪Hamburg, Germany
Krankenhaus Grosshansdorf, Zentrum fuer Pneumologie und Thoraxchirurgie
🇩🇪Grosshansdorf, Germany
Pest Megyei Tudogyogyintezet, III. Osztaly
🇭🇺Torokbalint, Hungary
Ospedale Versilia, Oncologia Medica
🇮🇹Lido di Camaiore (LU), Italy
Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Department of Oncology
🇬🇧London, United Kingdom
Ospedale Niguarda Ca' Granda Dipartimento Oncologico, SC Divisione di Oncologia Medica Falk
🇮🇹Milano, Italy
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
Oncologia Medica A
🇮🇹Genova, Italy
Orszagos Koranyi TBC es Pulmonologiai Intezet, VI. Bronchologia
🇭🇺Budapest, Hungary
Semmelweis Egyetem Pulmonologia Intezet
🇭🇺Budapest, Hungary
General Hospital of Chest Diseases of Athens "Sotiria"
🇬🇷Athens, Greece
Klinikum der Universitaet zu Koeln, Klinik I fuer Innere Medizin
🇩🇪Koeln, Germany
Klinikum der Universitaet Muenchen, Medizinische Klink - Innenstadt, Pneumologie
🇩🇪Muenchen, Germany
Aichi cancer center central hospital
🇯🇵Nagoya, Aichi, Japan
Kings College London at Guy's Hospital
🇬🇧London, United Kingdom
Hyogo Cancer Center
🇯🇵Akashi, Hyogo, Japan
Christie Hospital NHS Trust, Department of Medical Oncology
🇬🇧Manchester, United Kingdom
Nuffield Health Wessex Hospital
🇬🇧Eastleigh, United Kingdom
SUN Yat-Sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China
Cancer Institute and Hospital Chinese Academy of Medical Sciences and PUMC, Internal 4 Department
🇨🇳Beijing, China
307 Hospital of PLA
🇨🇳Beijing, China
Guangdong General Hospital
🇨🇳Guangzhou, China
Shanghai Chest Hospital
🇨🇳Shanghai, China
Zhongshan Hospital Fudan University / Respiratory Department
🇨🇳Shanghai, China
Shanghai Pulmonary Hospital
🇨🇳Shanghai, China
Nucleo de Oncologia da Bahia
🇧🇷Salvador, Bahia, Brazil
Wishard Memorial Hospital
🇺🇸Indianapolis, Indiana, United States
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Kaiser Permanente Colorado - Franklin
🇺🇸Denver, Colorado, United States
UCSD Medical Center - Hillcrest
🇺🇸San Diego, California, United States
Indiana University Hospital Clarian Health
🇺🇸Indianapolis, Indiana, United States
Indiana University Melvin and Bren Simon Cancer Center
🇺🇸Indianapolis, Indiana, United States
Ship drug to: Investigational Drug Services
🇺🇸Indianapolis, Indiana, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
Sarah Cannon Research Institute (Administration)
🇺🇸Nashville, Tennessee, United States
Sarah Cannon Research Institute (Pharmacy)
🇺🇸Nashville, Tennessee, United States
Vanderbilt Cancer Clinic
🇺🇸Nashville, Tennessee, United States
The Vanderbilt Chemo Clinic
🇺🇸Nashville, Tennessee, United States
Dipartimento Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative
🇮🇹Milano, Italy
Azienda Ospedaliera Universitaria San Luigi Gonzaga
🇮🇹Orbassano (TO), Italy
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Somers Cancer Research Building, M824
🇬🇧Southampton, United Kingdom
APHM - Hopital Nord / Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques
🇫🇷Marseille Cedex 20, France
Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology
🇦🇺East Melbourne, Victoria, Australia
UMHAT Tsaritsa Yoanna - ISUL
🇧🇬Sofia, Bulgaria
Merlin Park Imaging Centre
🇮🇪Galway, Ireland
Republican Clinical Oncology Dispensary of the Ministry of Health of Tatarstan Republic
🇷🇺Kazan, Russian Federation
MDOZS "Dr. Marko Markov", Otdelenie po onkoterapiya i paliativni grizhi
🇧🇬Varna, Bulgaria
Emory University Hospital
🇺🇸Atlanta, Georgia, United States
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
Taipei Veterans General Hospital, Chest Department
🇨🇳Taipei, Taiwan
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, Klinika po himioterapiya
🇧🇬Sofia, Bulgaria
General Hospital of Thessaloniki Georgios Papanikolaou, Lung Cancer Neoplasia Research Department
🇬🇷Exohi, Thessaloniki, Greece
Fejer Megyei Szent Gyorgy Korhaz, Pulmonologiai Osztaly
🇭🇺Szekesfehervar, Hungary
Dr. Georges-L. Dumont Regional Hospital
🇨🇦Moncton, New Brunswick, Canada
Debreceni Egyetem Orvos - es Egeszsegtudomanyi Centrum, Tudogyogyaszati Klinika
🇭🇺Debrecen, Hungary
Veszprem Megyei Onkormanyzat Tudogyogyintezete
🇭🇺Farkasgyepu, Hungary
Dr. Leon Richard Oncology Centre
🇨🇦Moncton, New Brunswick, Canada
Aseptic Compounding Unit
🇮🇪Dublin, Ireland
Pharmacy Aseptic Services Unit
🇮🇪Galway, Ireland
Royal Victoria Hospital
🇨🇦Montreal, Quebec, Canada
DRUG SHIPMENT: University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
Rocky Mountain Lions Eye Institute
🇺🇸Aurora, Colorado, United States
National Institutes of Health National Cancer Institute
🇺🇸Bethesda, Maryland, United States
H Lee Moffitt Cancer Center & Research Institute
🇺🇸Tampa, Florida, United States
Kaiser Permanente Colorado - Rock Creek
🇺🇸Lafayette, Colorado, United States
Tower Hematology Oncology Medical Group
🇺🇸Beverly Hills, California, United States
Santa Monica-UCLA Medical Center & Orthopaedic Hospital Clinical Laboratory
🇺🇸Santa Monica, California, United States
UCLA Hematology Oncology-Santa Monica
🇺🇸Santa Monica, California, United States
University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States
Comprehensive Blood and Cancer Center
🇺🇸Bakersfield, California, United States
Moores UCSD Cancer Center
🇺🇸La Jolla, California, United States
University of California, Irvine-Medical Center
🇺🇸Orange, California, United States
University of California, Irvine-Pharmacy
🇺🇸Orange, California, United States
University of Colorado Hospital
🇺🇸Aurora, Colorado, United States
Winship Cancer Institution
🇺🇸Atlanta, Georgia, United States
MCG Health Cancer Center Pharmacy
🇺🇸Augusta, Georgia, United States
Georgia Cancer Specialists-Macon
🇺🇸Macon, Georgia, United States
OnCare Hawaii, Inc.
🇺🇸Honolulu, Hawaii, United States
Georgia Cancer Specialists-Northside
🇺🇸Sandy Springs, Georgia, United States
Ingalls Memorial Hospital (Drug Shipment Only)
🇺🇸Harvey, Illinois, United States
The Harry and Jeanette Cancer Research Building
🇺🇸Baltimore, Maryland, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Siteman Cancer Center
🇺🇸St. Peters, Missouri, United States
Dartmouth Hitchcock Medical Center/Mary Hitchcock Memorial Hospital
🇺🇸Lebanon, New Hampshire, United States
North Shore University Hospital
🇺🇸Manhasset, New York, United States
Memorial Sloan - Kettering Cancer Center
🇺🇸New York, New York, United States
Presbyterian Hospital Matthews
🇺🇸Matthews, North Carolina, United States
The Ohio State University Investigational Drug Services
🇺🇸Columbus, Ohio, United States
Penn State Milton S. Hershey Medical Center, Penn State Hershey Cancer Institute
🇺🇸Hershey, Pennsylvania, United States
Tennessee Oncology, PLLC
🇺🇸Smyrna, Tennessee, United States
University of Texas Southwestern Medical Center at Dallas
🇺🇸Dallas, Texas, United States
Lisa Nakatsu, RPh (Drug Shipment Address)
🇺🇸Seattle, Washington, United States
Instituto Nacional do Câncer - INCA
🇧🇷Rio de Janeiro, RJ, Brazil
Irmandade da Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, RS, Brazil
Fundacao Pio XII Hospital de Cancer de Barretos
🇧🇷Barretos, SP, Brazil
Fundacao Antonio Prudente
🇧🇷Sao Paulo, SP, Brazil
RSM Durham Regional Cancer Centre - Lakeridge Health Oshawa
🇨🇦Oshawa, Ontario, Canada
Dr. Dana Blakolmer and Associates
🇨🇦Oshawa, Ontario, Canada
Hopital Tenon
🇫🇷Paris cedex 20, France
Centre Rene Gauducheau / Service d'Oncologie Medicale
🇫🇷St Herblain Cedex, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Universitaetsklinikum Carl-Gustav-Carus Dresden
🇩🇪Dresden, Germany
Thoraxklinik Heidelberg gGmbH
🇩🇪Heidelberg, Germany
Pius-Hospital Oldenburg
🇩🇪Oldenburg, Germany
HSK Dr.- Horst-Schmidt-Kliniken
🇩🇪Wiesbaden, Germany
University General Hospital of Heraklion/ Department of Clinical Oncology
🇬🇷Heraklion, Crete, Greece
Divisione di Oncologia Medica, Ospedale San Giuseppe Moscati, Citta' Ospedaliera
🇮🇹Avellino, Italy
S.C. Oncologia Medica
🇮🇹Firenze, Italy
Unita' Operativa Complessa di Pneumologia Oncologica I, Padiglione Flaiani
🇮🇹Roma, Italy
Kinki University Hospital
🇯🇵Osakasayama-shi, Osaka, Japan
National Cancer Center Hospital
🇯🇵Chuo-ku, Tokyo, Japan
National Hospital Organization Hokkaido Cancer Center
🇯🇵Sapporo, Hokkaido, Japan
Shizuoka Cancer Center
🇯🇵Sunto-gun, Shizuoka, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
National Cancer Center, Center for Lung Cancer
🇰🇷Gyeonggi-do, Korea, Republic of
Seoul National University Hospital / Department of Internal Medicine
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center, Sungkyunkwan Univ School of Medicine
🇰🇷Seoul, Korea, Republic of
Universitair Medisch Centrum Groningen
🇳🇱Groningen, Netherlands
Pracownia Optyczna Bozena Lawrynowicz Optyk Dyplomowany
🇵🇱Olsztyn, Poland
State Institution "National Cancer Research Center named after N.N. Blokhin' RAMS"
🇷🇺Moscow, Russian Federation
Ars Medica
🇵🇱Olsztyn, Poland
Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc
🇵🇱Olsztyn, Poland
Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii
🇵🇱Poznan, Poland
Wojewodzki Szpital Specjalistyczny w Olsztynie, Zaklad Medycyny Nuklearnej
🇵🇱Olsztyn, Poland
Zaklad Diagnostyki Obrazowej
🇵🇱Poznan, Poland
Saint-Petersburg State Medical University named after I.P.Pavlov of Roszdrav
🇷🇺Saint-Petersburg, Russian Federation
City Clinical Oncology Dispensary
🇷🇺St. Petersburg, Russian Federation
Research Institute of Pulmonology
🇷🇺Saint-Petersburg, Russian Federation
Hospital Universitari Germans Trias I Pujol
🇪🇸Badalona, Barcelona, Spain
Institut Catala D'Oncologia - Hospital Duran I Reynals
🇪🇸L'hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Central de Asturias
🇪🇸Oviedo, Asturias, Spain
Complexo Hospitalario Universitario A Coruña
🇪🇸A Coruña, Galicia, Spain
Consorcio Hospitalario Parc Tauli
🇪🇸Sabadell, Barcelona, Spain
Hospital General Universitari Vall D´Hebron
🇪🇸Barcelona, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital de Navarra
🇪🇸Pamplona, Spain
Hospital Universitario Marques de Valdecilla
🇪🇸Santander, Spain
Hospital Universitario Virgen Del Rocio
🇪🇸Sevilla, Spain
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Karolinska Universitetssjukhuset, Onkologiska kliniken
🇸🇪Stockholm, Sweden
National Taiwan University Hospital, Department of Internal Medicine
🇨🇳Taipei, Taiwan
Royal Marsden Hospital
🇬🇧London, United Kingdom
Cancer and Haematology Centre,
🇬🇧Headington, Oxford, United Kingdom
University of California-Los Angeles
🇺🇸Santa Monica, California, United States
Hospital Del Mar
🇪🇸Barcelona, Spain
Tower Cancer Research Foundation
🇺🇸Beverly Hills, California, United States
University of Hawaii - Cancer Research Center of Hawaii
🇺🇸Honolulu, Hawaii, United States
The Ohio State University James Cancer Hospital and Solove Research Institute
🇺🇸Columbus, Ohio, United States
Okayama University Hospital
🇯🇵Okayama, Japan
Michael and Dianne Bienes Cancer Center, Holy Cross Hospital
🇺🇸Fort Lauderdale, Florida, United States
MCG Health System Pharmacy (Drug Shipment Only)
🇺🇸Augusta, Georgia, United States
Georgia Cancer Specialists-Kennestone
🇺🇸Marietta, Georgia, United States
Yale University
🇺🇸New Haven, Connecticut, United States
Smilow Cancer Hospital at Yale New Haven
🇺🇸New Haven, Connecticut, United States
UC Davis Cancer Center
🇺🇸Sacramento, California, United States
University of California Davis Medical Center
🇺🇸Sacramento, California, United States
Smilow Cancer Center at Yale New Haven, Oncology Pharmacy
🇺🇸New Haven, Connecticut, United States
UNC Health Care
🇺🇸Chapel Hill, North Carolina, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Medical University of South Carolina - Hollings Cancer Center
🇺🇸Charleston, South Carolina, United States
Division of Respiratory and Critical Care Medicine, Department of Medicine, Queen Mary Hospital
🇭🇰Pokfulam, Hong Kong
Department of Clinical Oncology, Prince of Wales Hospital
🇭🇰Shatin, New Territories, Hong Kong
Tuen Mun Hospital, Department of Clinical Oncology
🇭🇰Tuen Mun, New Territories, Hong Kong